Cargando…
Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A
Background: A more effective vaccine for tuberculosis (TB) is a global public health priority. Vaccines under development will always need evaluation in endemic settings, most of which have limited resources. Adolescents are an important target population for a new TB vaccine and for other vaccines...
Autores principales: | Wajja, Anne, Namutebi, Milly, Apule, Barbara, Oduru, Gloria, Kiwanuka, Samuel, Akello, Mirriam, Nassanga, Beatrice, Kabagenyi, Joyce, Mpiima, Juma, Vermaak, Samantha, Lawrie, Alison, Satti, Iman, Verweij, Jaco, Cose, Stephen, Levin, Jonathan, Kaleebu, Pontiano, Tukahebwa, Edridah, McShane, Helen, Elliott, Alison M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338128/ https://www.ncbi.nlm.nih.gov/pubmed/30687792 http://dx.doi.org/10.12688/wellcomeopenres.14736.1 |
Ejemplares similares
-
The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
por: Wajja, Anne, et al.
Publicado: (2017) -
Population differences in vaccine responses (POPVAC): scientific rationale and cross-cutting analyses for three linked, randomised controlled trials assessing the role, reversibility and mediators of immunomodulation by chronic infections in the tropics
por: Nkurunungi, Gyaviira, et al.
Publicado: (2021) -
The Lake Victoria island intervention study on worms and allergy-related diseases (LaVIISWA): study protocol for a randomised controlled trial
por: Nampijja, Margaret, et al.
Publicado: (2015) -
Impact of BCG revaccination on the response to unrelated vaccines in a Ugandan adolescent birth cohort: randomised controlled trial protocol C for the ‘POPulation differences in VACcine responses’ (POPVAC) programme
por: Zirimenya, Ludoviko, et al.
Publicado: (2021) -
A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults
por: Minhinnick, Alice, et al.
Publicado: (2016)